Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
The DOI matches its Crossref record; 111 of the 112 references it cites were found in a registry or an index.
Abstract
Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critical component of managing the condition are well established, weight reduction remains challenging for individuals with type 2 diabetes due to a host of metabolic and psychological factors. For many patients, lifestyle intervention is not enough to achieve weight loss, and alternative options, such as pharmacotherapy, need to be considered. However, many traditional glucose-lowering medications may lead to weight gain. This article focuses on the potential of currently available pharmacological strategies and on emerging approaches in development to support the glycemic and weight-loss goals of individuals with type 2 diabetes. Two pharmacotherapy types are considered: those developed primarily for blood glucose control that have a favorable effect on body weight and those developed primarily to induce weight loss that have a favorable effect on blood glucose control. Finally, the potential of combination therapies for the management of obese patients with type 2 diabetes is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Weight reduction, therefore, is a key therapeutic goal in both the prevention and management of type 2 diabetes (5).”
BackgroundMechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 1×
“Obesitydin particular abdominal obesitydis a major driver in the development of diabetes and cardiovascular disease (2), with the increasing prevalence of obesity mirrored by the rising prevalence of diabetes (3).”
BackgroundXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 1×
“Orlistat was generally well tolerated, and gastrointestinal effects were the most commonly reported AEs, but all events were considered mild or moderate (75,76).”
BackgroundYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“GLP-1/GLP-1R signaling increases b-cell sensitivity to glucose and suppresses glucagon secretion frompancreatic a-cells (38,39).”
BackgroundAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
(2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.334 · Cited by 1,162
Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons
Woods, S. C., Lotter, E. C., McKay, L. D., & Porte, D. (1979) · Nature · doi:10.1038/282503a0 · Cited by 1,114
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 1×
“Dapagliflozin-induced body weight has been shown to occur through reductions in fatmass, visceral fat, and subcutaneous fat (57,58).”
BackgroundEight-year weight losses with an intensive lifestyle intervention: The look AHEAD study
The Look AHEAD Research Group (2014) · Obesity · doi:10.1002/oby.20662 · Cited by 842
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 2×
“agonist (103) c Acts on receptors for both GLP-1 and GIP”
BackgroundIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Stenlöf, K., Cefalu, W. T., Kim, K. ‐., Alba, M., Usiskin, K., Tong, C., Canovatchel, W., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12054 · Cited by 614
Insulin‐associated weight gain in diabetes – causes, effects and coping strategies
Russell‐Jones, D., & Khan, R. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00686.x · Cited by 557
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Self-citationFoster, G. D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.266 · Cited by 538
O'Neil, P. M., Smith, S. R., Weissman, N. J., Fidler, M. C., Sanchez, M., Zhang, J., Raether, B., Anderson, C. M., & Shanahan, W. R. (2012) · Obesity · doi:10.1038/oby.2012.66 · Cited by 530
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501 · cited 2×
“It is interesting to note that the reductions in HbA1c observed with lorcaserin are equal to or higher than those observed with other antiobesity agents, such as phentermine plus topiramate and NB, despite a smaller amount of weight loss (71,73,80).”
BackgroundResultPancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Roizen, M. F. (2011) · Yearbook of Anesthesiology and Pain Management · doi:10.1016/j.yane.2011.01.029 · Cited by 487
Bolinder, J., Ljunggren, Ö., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 482
Biology's response to dieting: the impetus for weight regain
MacLean, P. S., Bergouignan, A., Cornier, M.-A., & Jackman, M. R. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00755.2010 · Cited by 446
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
Anti-obesity drugs: past, present and future
Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. H. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.009621 · Cited by 430
Rosenbaum, M., Sy, M., Pavlovich, K., Leibel, R. L., & Hirsch, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35055 · Cited by 407
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial
The DCCT Research Group (1988) · Diabetes Care · doi:10.2337/diacare.11.7.567 · Cited by 345
Toft-Nielsen, M. B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 338
Mäkimattila, S., Nikkilä, K., & Yki-Järvinen, H. (1999) · Diabetologia · doi:10.1007/s001250051172 · Cited by 314
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Riddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas
Tornehave, D., Kristensen, P., Rømer, J., Knudsen, L. B., & Heller, R. S. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.951319 · Cited by 248
Perkins, B. A., Cherney, D. Z. I., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., Fagan, N. M., Kaspers, S., Woerle, H.-J., Broedl, U. C., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2338 · Cited by 231
Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010) · Diabetes Care · doi:10.2337/dc09-1203 · Cited by 229
Blonde, L., & Russell‐Jones, D. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01075.x · Cited by 227
for the OBES-002 Study Group, Wilding, J., Gaal, L. V., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802783 · Cited by 224
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis
Liakos, A., Karagiannis, T., Athanasiadou, E., Sarigianni, M., Mainou, M., Papatheodorou, K., Bekiari, E., & Tsapas, A. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12307 · Cited by 219
Fibroblast growth factor 21: from pharmacology to physiology
Kliewer, S. A., & Mangelsdorf, D. J. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28449b · Cited by 219
The Look AHEAD Research Group (2014) · Diabetes Care · doi:10.2337/dc13-1928 · Cited by 217
Devenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A. (2012) · Obesity · doi:10.1038/oby.2012.59 · Cited by 212 · cited 2×
“The effect of GLP-1R agonists on satiety may weaken the compensatory “overeating” mechanism observed with SGLT2 inhibition and enhance weight loss by SGLT2 inhibitors (63).”
BackgroundResultHypoglycemia Activates Orexin Neurons and Selectively Increases Hypothalamic Orexin-B Levels
Cai, X. J., Evans, M. L., Lister, C. A., Leslie, R. A., Arch, J. R. S., Wilson, S., & Williams, G. (2001) · Diabetes · doi:10.2337/diabetes.50.1.105 · Cited by 206
Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
Scheen, A. J., & Van Gaal, L. F. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70004-x · Cited by 190
Self-citationAbnormal glucose metabolism in patients treated with antipsychotics
Scheen, A. J., & De Hert, M. A. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.01.003 · Cited by 181
Self-citationBodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
Hermansen, K., & Mortensen, L. S. (2007) · Drug Safety · doi:10.2165/00002018-200730120-00005 · Cited by 174
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
Bays, H. E., Weinstein, R., Law, G., & Canovatchel, W. (2014) · Obesity · doi:10.1002/oby.20663 · Cited by 166 · cited 1×
“Canagliflozin (50–300 mg) has also been reported to have beneficial weight effects in overweight or obese individuals without diabetes (61).”
BackgroundDiamant, M., van Gaal, L., Guerci, B., Stranks, S., Han, J., Malloy, J., Boardman, M. K., & Trautmann, M. (2014) · The Lancet Diabetes and Endocrinology · doi:10.1016/s2213-8587(14)70029-4 · Cited by 163
Stenlöf, K., Cefalu, W. T., Kim, K.-A., Jodar, E., Alba, M., Edwards, R., Tong, C., Canovatchel, W., & Meininger, G. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.850066 · Cited by 158
Dushay, J. R., Gao, C., Gopalakrishnan, G. S., Crawley, M. B., Mitten, E. K., Wilker, E. H., Mullington, J. M., & Maratos–Flier, E. (2011) · Diabetes Care · doi:10.2337/dc11-0931 · Cited by 155
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
Garvey, W. T., Ryan, D. H., Bohannon, N. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014) · Diabetes Care · doi:10.2337/dc14-0930 · Cited by 149
The future role of gut hormones in the treatment of obesity
Troke, R., Tan, T., & Bloom, S. R. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313506730 · Cited by 143
Clemmensen, C., Chabenne, J., Finan, B., Sullivan, L., Fischer, K., Küchler, D., Sehrer, L., Ograjsek, T., Hofmann, S. M., Schriever, S. C., et al. (2014) · Diabetes · doi:10.2337/db13-1609 · Cited by 136
Zhang, M., Zhang, L., Wu, B., Song, H.-L., An, Z., & Li, S. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2479 · Cited by 129
Berne, C., & the Orlistat Swedish Type 2 diabetes Study Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01474.x · Cited by 119
Effect of Obesity on the Response to Insulin Therapy in Noninsulin-Dependent Diabetes Mellitus
Yki‐Järvinen, H., Ryysy, L., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., NISKANEN, L. K., Rajala, S., Salo, S., Seppälä, P., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4460 · Cited by 118
Eriksson, H., Ridderstråle, M., Degerman, E., Ekholm, D., Smith, C. J., Manganiello, V. C., Belfrage, P., & Tornqvist, H. E. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(94)00237-9 · Cited by 116
Weight Loss in Type 2 Diabetic Patients
Pi-Sunyer, X. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1526 · Cited by 101
Niswender, K., Pi‐Sunyer, X., Buse, J., Jensen, K. H., Toft, A. D., Russell‐Jones, D., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01673.x · Cited by 100
Pramlintide and the treatment of diabetes: a review of the data since its introduction
Younk, L. M., Mikeladze, M., & Davis, S. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.581663 · Cited by 100
Göke, R., Wagner, B., Fehmann, H. C., & Göke, B. (1993) · Research in Experimental Medicine · doi:10.1007/bf02576216 · Cited by 96
Usiskin, K., Kline, I., Fung, A., Mayer, C., & Meininger, G. E. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2753 · Cited by 93
Toft, U., Kristoffersen, L., Aadahl, M., Smith, L. V. H., Pisinger, C. H., & Jørgensen, T. (2006) · European Journal of Public Health · doi:10.1093/eurpub/ckl262 · Cited by 92
Thiazolidinediones, insulin resistance and obesity: finding a balance
Wilding, J. P. H. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01128.x · Cited by 90
Berhan, A., & Barker, A. J. (2013) · BMC Endocrine Disorders · doi:10.1186/1472-6823-13-58 · Cited by 86
Rosenstock, J., Hollander, P., Gadde, K. M., Sun, X., Strauss, R., Leung, A., & for the OBD-202 Study Group (2007) · Diabetes Care · doi:10.2337/dc06-2001 · Cited by 85
Liebl, A., Hoogma, R. P. L. M., Renard, É., Geelhoed-Duijvestijn, P. H. L. M., Klein, E., Diglas, J., Kessler, L., Melki, V., Diem, P., Brun, J. M., et al. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01059.x · Cited by 83
Omar, B. A., Andersen, B., Hald, J., Raun, K., Nishimura, E., & Åhrén, B. (2013) · Diabetes · doi:10.2337/db13-0710 · Cited by 82
Jacob, S., Rabbia, M. A., Meier, M. K., & Hauptman, J. B. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00970.x · Cited by 78
Efficacy and Safety of Topiramate in the Treatment of Obese Subjects With Essential Hypertension
Tonstad, S., Tykarski, A., Weissgarten, J., Ivleva, A. Y., Levy, B., Kumar, A., & Fitchet, M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.03.053 · Cited by 77
Singh‐Franco, D., Perez, A., & Harrington, C. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01337.x · Cited by 76
Hughes, T. E., Kim, D. D., Marjason, J. K., Proietto, J., Whitehead, J. P., & Vath, J. E. (2013) · Obesity · doi:10.1002/oby.20356 · Cited by 70
Meneghini, L., Kesavadev, J., Demissie, M., Nazeri, A., & Hollander, P. A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12083 · Cited by 65
New pharmacological approaches for obesity management
Rueda‐Clausen, C. F., Padwal, R. S., & Sharma, A. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.113 · Cited by 61
Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time
Gallwitz, B., Vaag, A. A., Falahati, A., & Madsbad, S. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02265.x · Cited by 59
Derosa, G., Cicero, A. F. G., D’Angelo, A., Fogari, E., & Maffioli, P. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01280.x · Cited by 57
Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial
Fonseca, V. A., McDuffie, R. H., Calles, J., Cohen, R. M., Feeney, P. A., Feinglos, M. N., Gerstein, H. C., Ismail‐Beigi, F., Morgan, T. M., Pop‐Busui, R., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1391 · Cited by 57
GLP-1R agonist therapy for diabetes: benefits and potential risks
Samson, S. L., & Garber, A. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835edb32 · Cited by 55
Novel strategy for the use of leptin for obesity therapy
Tam, C. S., Lecoultre, V., & Ravussin, É. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.619974 · Cited by 54
Fadini, G. P., Simioni, N., Frison, V., Pos, M. D., Bettio, M., Rocchini, P., & Avogaro, A. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0489-3 · Cited by 52
Pencek, R., Blickensderfer, A., Li, Y., Brunell, S. C., & Chen, S. (2012) · International journal of clinical practice · doi:10.1111/j.1742-1241.2012.03006.x · Cited by 51
van Dieren, S., Czernichow, S., Chalmers, J. P., Kengne, A. P., de Galan, B. E., Poulter, N. R., Woodward, M., Beulens, J. W. J., Grobbee, D. E., van der Schouw, Y. T., et al. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01556.x · Cited by 49
Esposito, K., Mosca, C., Brancario, C., Chiodini, P., Ceriello, A., & Giugliano, D. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.590127 · Cited by 47
Decreased Basal Levels of Glucagon-Like Peptide-1 after Weight Loss in Obese Subjects
de Luis, D. A., Sagrado, M. G., Conde, R., Aller, R., & Izaola, O. (2007) · Annals of Nutrition and Metabolism · doi:10.1159/000103273 · Cited by 42
Characterizing and understanding body weight patterns in patients treated with pregabalin
Cabrera, J., Emir, B., Dills, D. G., Murphy, T. K., Whalen, E., & Clair, A. G. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.684044 · Cited by 42
Moon, H. S., Chamberland, J. P., & Mantzoros, C. S. (2011) · Diabetologia · doi:10.1007/s00125-011-2332-0 · Cited by 39
Tatarkiewicz, K., Sablan, E. J., Polizzi, C. J., Villescaz, C., & Parkes, D. G. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00495.2013 · Cited by 31
Leptin therapy in type 2 diabetes
Cummings, B. P. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12048 · Cited by 27
Katsiki, N., Hatzitolios, A. I., & Mikhailidis, D. P. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.541490 · Cited by 27
Bariatric surgery to treat type 2 diabetes: what is the recent evidence?
Gaal, L. F. V., & Block, C. E. M. D. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328357f0e0 · Cited by 26
Grasso, P. (2011) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/187221411797265917 · Cited by 16
Cardiovascular Risk Assessment in the Development of New Drugs for Obesity
Hiatt, W. R., Goldfine, A. B., & Kaul, S. (2012) · JAMA · doi:10.1001/jama.2012.9931 · Cited by 15
Heine, R. J., Fu, H., Kendall, D. M., & Moller, D. E. (2013) · Diabetes · doi:10.2337/db13-0690 · Cited by 14
Buse, J. B., Gough, S. C. L., Woo, V. C., Rodbard, H. W., Linjawi, S., Poulsen, P., mgaard, L. H. D., & Bode, B. W. (2013) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-013-0026-6 · Cited by 12
Araújo, F., Shrestha, N., Granja, P. L., Hirvonen, J. J., Santos, H. A., & Sarmento, B. F. C. C. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140915150312 · Cited by 9
Efficacy and safety of exenatide once weekly: an overview of the DURATION trials
Block, C. D., & van Gaal, L. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.51 · Cited by 3
Research works printed but not linked: 1
- Ferrannini, 2014, Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition, Diabetologia, 57, S8
Cited by
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495
The Role of Obesity in Type 2 Diabetes Mellitus—An Overview
Chandrasekaran, P., & Weiskirchen, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031882 · Cited by 465
Leitner, D. R., Frühbeck, G., Yumuk, V., Schindler, K., Micic, D., Woodward, E., & Toplak, H. (2017) · Obesity Facts · doi:10.1159/000480525 · Cited by 431
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Metadata
- Authors
- Van Gaal, L., & Scheen, A.
- Affiliations
- Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium
- University of Liège (BE)
- ORCID
- Scheen, André
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-05-12
- Volume
- 38
- Issue
- 6
- Pages
- 1161-1172
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1893948433
- Cited by
- 221
- References
- 112
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 22 · 2023: 19 · 2022: 17 · 2021: 18 · 2020: 24 · 2019: 23 · 2018: 22 · 2017: 27 · 2016: 24 · 2015: 8
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, obesity, weight management, weight loss, pharmacotherapy, glucose-lowering medications, anti-obesity drugs, glycemic control, combination therapy, lifestyle intervention
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Therapy, Combination, Forecasting, Humans, Hypoglycemic Agents, Obesity, Weight Gain, Weight Loss, Anti-Obesity Agents, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.